Loading…
AVITA Medical, Inc. is projected to rise to $4.91 by 2027, a +17% move from its current price of $4.20. RCEL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.05 | $4.20 | $4.36 | +0.01% |
| May 30 | $3.99 | $4.20 | $4.43 | +0.02% |
| May 31 | $3.94 | $4.20 | $4.48 | +0.03% |
| Jun 1 | $3.90 | $4.20 | $4.53 | +0.04% |
| Jun 2 | $3.87 | $4.20 | $4.57 | +0.05% |
| Jun 3 | $3.84 | $4.20 | $4.60 | +0.06% |
| Jun 4 | $3.81 | $4.20 | $4.64 | +0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.81 | $4.20 | $4.64 | +0.07% |
| Week 2 | $3.66 | $4.21 | $4.83 | +0.15% |
| Week 3 | $3.55 | $4.21 | $4.99 | +0.22% |
| Week 4 | $3.46 | $4.21 | $5.13 | +0.29% |
| Week 5 | $3.39 | $4.22 | $5.25 | +0.37% |
| Week 6 | $3.32 | $4.22 | $5.36 | +0.44% |
| Week 7 | $3.26 | $4.22 | $5.47 | +0.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AVITA Medical, Inc. is a healthcare company that operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. Its lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
The company also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors.
The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
AVITA Medical, Inc. trades under the RCEL symbol. The current price is $4.20 with a market cap of $129.26M, and it is ranked 4057 by market cap and liquidity metrics. The stock shows a mixed near-term stance with a neutral overall sentiment and a 30-day trading range that reflects some volatility but an ongoing interest from traders.
The company’s long-run forecast envisions multiple years of price appreciation, with 2026 starting at a neutral footing and subsequent years showing rising averages and strong ROIs while preserving a pathway to substantial future gains.
A major floor 18.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.1% away) — a key level to hold.
The nearest ceiling, 22.9% above — a clean break opens room to run.
A major ceiling 33.3% above — clearing it would confirm fresh momentum.
Key RCEL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RCEL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.37 | Sell | $4.31 | Sell |
| MA 10 | $4.34 | Sell | $4.33 | Sell |
| MA 20 | $4.32 | Sell | $4.36 | Sell |
| MA 50 | $4.33 | Sell | $4.37 | Sell |
| MA 100 | $4.29 | Sell | $4.37 | Sell |
| MA 200 | $4.33 | Sell | $4.80 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.90 | Neutral |
| Stoch RSI (14) | 23.67 | Neutral |
| CCI (20) | -75.60 | Neutral |
| Williams %R (14) | -80.85 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 2.19 | Buy |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 19.15 | Buy |
| TRIX (15) | -0.11 | Sell |
| Awesome (5,34) | -0.16 | Sell |
| Ultimate (7,14,28) | 38.18 | Neutral |
| Momentum (10) | -0.18 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 4.38 | Sell |
| ADX (14) | 8.56 | Neutral |
| ATR (14) | 0.16 | Info |
The 30-day picture is NEUTRAL overall. The RSI(14) sits at 50, and the short- to mid-term moving averages are both at $4.33 (SMA50 and SMA200). Support is identified at $4.11 and resistance at $5.16, framing a 30-day range from $3.29 to $5.36.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.28 | $4.20 | $5.69 | 0% | Neutral | |
| $3.76 | $4.91 | $6.87 | +17% | Neutral | |
| $3.81 | $5.17 | $7.57 | +23% | Bullish | |
| $3.61 | $5.07 | $7.70 | +21% | Bullish | |
| $4.96 | $7.16 | $11.20 | +70% | Bullish | |
| $5.97 | $8.85 | $14.22 | +111% | Bullish | |
| $5.85 | $8.89 | $14.62 | +112% | Bullish | |
| $6.29 | $9.79 | $16.46 | +133% | Bullish | |
| $5.90 | $9.39 | $16.10 | +124% | Bullish | |
| $6.17 | $10.05 | $17.55 | +139% | Bullish | |
| $8.48 | $15.29 | $28.78 | +264% | Bullish | |
| $17.11 | $37.19 | $77.99 | +785% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.28 | $4.20 | $4.97 | +0.00% |
| June 2026 | $3.68 | $4.35 | $5.30 | +3.61% |
| July 2026 | $3.54 | $4.24 | $5.26 | -2.56% |
| August 2026 | $3.39 | $4.10 | $5.15 | -3.29% |
| September 2026 | $3.46 | $4.22 | $5.36 | +2.85% |
| October 2026 | $3.52 | $4.31 | $5.54 | +2.31% |
| November 2026 | $3.44 | $4.24 | $5.50 | -1.64% |
| December 2026 | $3.51 | $4.36 | $5.69 | +2.70% |
Click any year to see its month-by-month RCEL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RCEL could reach as high as $5.69, with a base case around $4.20 and support toward $3.28 — roughly 0% from $4.20. A consolidation phase looks the most probable path here.
Expect RCEL to range from $3.76 to $6.87 through 2027. The $4.91 average target implies a +17% move from current prices. That is up +17% on the projected 2026 average. Price action looks broadly range-bound.
The RCEL price prediction for 2028 points to an average of $5.17 (low $3.81, high $7.57) — a potential gain of +23% on today's $4.20. Buyers look set to stay in control over this stretch.
In 2029, RCEL is projected to trade between $3.61 and $7.70, averaging $5.07 — a potential gain of +21% from today's $4.20. That is -2% versus the projected 2028 average. Momentum favours further upside here.
AVITA Medical, Inc.'s 2030 outlook centres on $7.16, within a $4.96 to $11.20 range. That is up +41% on the projected 2029 average. That marks a +70% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, RCEL could reach as high as $14.22, with a base case around $8.85 and support toward $5.97 — roughly +111% from $4.20. Momentum favours further upside here.
Expect RCEL to range from $5.85 to $14.62 through 2032. The $8.89 average target implies a +112% move from current prices. That is up 0% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The RCEL price prediction for 2033 points to an average of $9.79 (low $6.29, high $16.46) — a potential gain of +133% on today's $4.20. Momentum favours further upside here.
In 2034, RCEL is projected to trade between $5.90 and $16.10, averaging $9.39 — a potential gain of +124% from today's $4.20. That is -4% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
AVITA Medical, Inc.'s 2035 outlook centres on $10.05, within a $6.17 to $17.55 range. That is up +7% on the projected 2034 average. That marks a +139% change versus current levels. Momentum favours further upside here.
By 2040, RCEL could reach as high as $28.78, with a base case around $15.29 and support toward $8.48 — roughly +264% from $4.20. Buyers look set to stay in control over this stretch.
Expect RCEL to range from $17.11 to $77.99 through 2050. The $37.19 average target implies a +785% move from current prices. That is up +143% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in RCEL today (≈ 238.095238 RCEL) could be worth
$8,854.08
+$7,854.08 (+785%) by 2050 · US Dollar
Based on the average projected RCEL price of $37.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RCELwould be worth at today's price.
$1,000 invested in RCEL on May 27, 2025 (≈ 164.744641 RCEL) would be worth
$691.93
-$308.07 (-30.8%) today · 0.69× · US Dollar
Based on a RCEL entry price of $6.07 vs. today's $4.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.32 | $972.22 | -2.8% |
| 1 month ago | $4.56 | $921.05 | -7.9% |
| 3 months ago | $5.11 | $821.92 | -17.8% |
| 6 months ago | $3.7 | $1,135.14 | +13.5% |
| 1 year ago | $6.07 | $691.93 | -30.8% |
| All time (5.0y) ago | $17.84 | $235.43 | -76.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RCEL forecast.
Our base-case forecast reaches $8.40 around 2031.
Implied market cap at $8.40: $258.52M
The multi-year forecast starts with a neutral 2026, where min $3.28, avg $4.20, max $5.69 and ROI 0 are projected. From 2027 onward the outlook turns bullish, with 2027 at avg $4.91 and ROI 16.9, 2028 at avg $5.17 and ROI 23.1, and 2029 at avg $5.07 and ROI 20.7. By 2030 the average climbs to $7.16 with a 70.4% ROI, followed by 2031 at $8.85 (110.7%), 2032 at $8.89 (111.6%), and 2033 at $9.79 (133.2%), then 2034 at $9.39 (123.7%) and 2035 at $10.05 (139.4%).
The trajectory continues with 2040 at $15.29 (264.2%) and 2050 at $37.19 (785.4%). These figures reflect a bullish long-run path with substantial upside, though they are estimates and not guarantees.
Tap a question to reveal the answer.
Avg $7.16, ROI 70.4%.
Forecasts show a bullish trajectory from 2027 onward with rising averages and high ROI by 2050 (avg $37.19; ROI 785.4%). These are estimates and not guarantees.
Yes. The 2035 forecast lists avg $10.05 and max $17.55.
Current price is $4.20 and market cap is $129.26M.
$3.29 to $5.36.
AVITA Medical, Inc. Community Discussion
0Share your AVITA Medical, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.